Drug Trial Radar · NCT03380793
A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis
Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
614
Planned (sponsor's estimate)
Start
Sep 2016
Primary completion
Oct 2018
Study completion Oct 2018
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy, safety, tissue distribution of target organ and Population Pharmacokinetic (PPK) of morinidazole and sodium chloride injection with surgery in patients with suppurative or gangrenous appendicitis
Conditions
- Appendicitis
Interventions
morinidazoleDrug
morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical cure RateTime frame: 5-10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PLA General Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.